Media.Player

Alpha 7 nicotinic allosteric modulators and their derivatives

技術優勢

-Potential therapeutics for a wide range of disorders that require enhancement of α7 nAChR. -The compounds can be formulated in a variety means to suit the pharmaceutical needs.

技術應用

The present invention may be used to treat a variety of disorders, including of the central nervous system (CNS) and the peripheral nervous system (PNS). Such disorders of the CNS and the PNS include neurodegenerative diseases, senile dementias, schizophrenia, Alzheimer’s disease, learning, cognition and attention deficits, memory loss, Lewy Body dementia, attention-deficit disorder, attention deficit hyperactivity disorder, anxiety, mania, manic depression, Parkinson’ s disease, Huntington’ s disease, depression, amyotrophic lateral sclerosis, brain inflammation, cognitive deficit due to traumatic brain injury, and Tourette’s syndrome. Compounds of the invention are also useful in the treatment (therapeutic or prophylactic), prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson’s disease. In addition, compounds of the present invention may be used to treat immune system disorders, such as, but not limited to, type I diabetes, multiple sclerosis, and rheumatoid arthritis. In addition, compounds of the present invention may be used to treat pain, inflammation, septic shock, ulcerative colitis, irritable bowel syndrome and Crohn’s disease. Compounds of the invention are useful in tobacco cessation treatment, in the treatment of, and in treating jetlag. In addition, compounds of the invention are also of use in treating immune system disorders, Fragile X, autism spectrum disorder, Angelman’s syndrome, Rett syndrome, Prader Willi syndrome and Down’s syndrome.

詳細技術說明

α7 nAChRs are ion channels that recognize acetylcholine and choline as the endogenous ligand and also bind nicotine. In the brain, activation of neuronal α7 nAChRs plays an important role in synaptic transmission. An allosteric modulator of α7 nAChRs does not bind to the ligand-binding site on the α7 nAChR and cannot affect the functional state of the ion channel. It requires the presence of an agonist to activate the channel, and in-turn potentiates the action of the agonist. Researchers at UC Irvine discovered a class of novel positive allosteric modulators of α7 nAChRs. The compounds are potential therapeutics for the disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs. The compounds may be formulated and administered by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles.

*Abstract

A class of novel compounds that allosterically modulate the α7 nicotinic acetylcholine receptor (α7 nAChR) and may be used to treat disorders amenable to the modulation of the α7 nAChR.

*IP Issue Date

Apr 30, 2015

*Principal Investigation

Name: Derk Hogenkamp

Department:

申請號碼

20150119402

其他

Tech ID/UC Case

24660/2013-771-0

Related Cases

2013-771-0

國家/地區

美國